1. Home
  2. CCB vs NRIX Comparison

CCB vs NRIX Comparison

Compare CCB & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coastal Financial Corporation

CCB

Coastal Financial Corporation

HOLD

Current Price

$116.73

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$19.30

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCB
NRIX
Founded
1997
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
CCB
NRIX
Price
$116.73
$19.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
13
Target Price
$117.50
$27.46
AVG Volume (30 Days)
110.6K
1.9M
Earning Date
01-27-2026
01-27-2026
Dividend Yield
N/A
N/A
EPS Growth
6.19
N/A
EPS
3.17
N/A
Revenue
$343,667,000.00
$83,687,000.00
Revenue This Year
$85.02
$59.40
Revenue Next Year
$17.38
N/A
P/E Ratio
$36.93
N/A
Revenue Growth
26.18
48.32
52 Week Low
$76.11
$8.18
52 Week High
$120.05
$22.50

Technical Indicators

Market Signals
Indicator
CCB
NRIX
Relative Strength Index (RSI) 59.28 62.13
Support Level $112.57 $18.79
Resistance Level $120.05 $19.84
Average True Range (ATR) 3.44 1.13
MACD 0.01 -0.21
Stochastic Oscillator 70.82 37.06

Price Performance

Historical Comparison
CCB
NRIX

About CCB Coastal Financial Corporation

Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company. The maximum revenue of the company is generated from the CCBX segment.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: